Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting

被引：0
|
作者：
Gorantla, Vikram C.
Rui, Anna
Rosenfeld, Stephan B.
Kudrik, Fred J.
Vasudevan, Anupama
Sura, Teena
Gart, Mike
Kanovsky, Doug
Brenneman, Dawn
Varughese, Prateesh
Scott, Jeffrey A.
Choksi, Rushir J.
Geller, Robert B.
Blanc, Simon
机构：
[1] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA
[2] Integra Connect PrecisionQ, W Palm Beach, FL USA
[3] Highlands Oncol Grp, Fayetteville, AR USA
[4] South Carolina Oncol Associates, W Columbia, SC USA
[5] Integra Connect, W Palm Beach, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13169
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine.
    Gorantla, Vikram C.
    Rui, Anna
    Rosenfeld, Stephan B.
    Kudrik, Fred J.
    Vasudevan, Anupama
    Sura, Teena
    Gart, Mike
    Kanovsky, Doug
    Brenneman, Dawn
    Varughese, Prateesh
    Scott, Jeffrey A.
    Choksi, Rushir J.
    Geller, Robert B.
    Blanc, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [3] FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
    Narayan, Preeti
    Osgood, Christy L.
    Singh, Harpreet
    Chiu, Haw-Jyh
    Ricks, Tiffany K.
    Chow, Edwin Chiu Yuen
    Qiu, Junshan
    Song, Pengfei
    Yu, Jingyu
    Namuswe, Frances
    Guiterrez-Lugo, Maria
    Hou, Sherry
    Pierce, William F.
    Goldberg, Kirsten B.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4478 - 4485
  • [4] FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
    Mehta, Gautam U.
    Vellanki, Paz J.
    Ren, Yi
    Amatya, Anup K.
    Mishra-Kalyani, Pallavi S.
    Pan, Lili
    Zirkelbach, Jeanne F.
    Pan, Yuzhuo
    Liu, Jiang
    Aungst, Stephanie L.
    Miller, Claudia P.
    Shah, Mirat
    Rahman, Nam Atiqur
    Theoret, Marc
    Kluetz, Paul
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    ONCOLOGIST, 2024, 29 (08): : 667 - 671
  • [5] US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
    Narayan, Preeti
    Dilawari, Asma
    Osgood, Christy
    Feng, Zhou
    Bloomquist, Erik
    Pierce, William F.
    Jafri, Samina
    Kalavar, Shyam
    Kondratovich, Marina
    Jha, Prakash
    Ghosh, Soma
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2108 - +
  • [6] Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer
    Alqam, Anas
    Zakhour, Joud
    Karam, Wissam
    Ashkar, Ryan
    Okut, Hayrettin
    Dakhil, Shaker R.
    Dakhil, Christopher
    Mattar, Bassam Ibrahim
    Koeneke, Travis Lee
    Moore, Dennis Frederic, Jr.
    Moore, Joseph A.
    Van Truong, Phu
    Van Truong, Quoc
    Page, Seth Joel
    Reddy, Pavan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
    Moser, Sarah Sharman
    Apter, Lior
    Livnat, Idit
    Ginsburg, Roni
    Yarden, Adva
    Drori, Michal
    Drizon, Anat
    Chodick, Gabriel
    Siegelmann-Danieli, Nava
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 105 - 116
  • [8] Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer
    Tarantino, Paolo
    Lee, Do
    Foldi, Julia
    Soulos, Pamela R.
    Gross, Cary Philip
    Grinda, Thomas
    Winer, Eric P.
    Lin, Nancy U.
    Krop, Ian E.
    Tolaney, Sara M.
    Lustberg, Maryam B.
    Sammons, Sarah L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] The Real-World Clinical Outcomes of Heavily Pretreated HER2+and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
    Lazaratos, Anna-Maria
    Dankner, Matthew
    Hamouda, Aalya
    Labidi, Soumaya
    Cohen, Victor
    Panasci, Lawrence
    Friedmann, Jennifer E.
    Patenaude, Francois
    Ferrario, Cristiano
    Basik, Mark
    Rose, April A. N.
    Fallah, Parvaneh
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [10] Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+Metastatic Breast Cancer: The DE-REAL Study
    Botticelli, Andrea
    Caputo, Roberta
    Scagnoli, Simone
    Pisegna, Simona
    De Laurentiis, Michelino
    Curigliano, Giuseppe
    Lambertini, Matteo
    Pantano, Francesco
    Palazzo, Antonella
    Paris, Ida
    Vernieri, Claudio
    Tedesco, Beatrice
    Giampaglia, Marianna
    Palleschi, Michela
    Ballatore, Zelmira
    Alesini, Daniele
    D'Auria, Giuliana
    Fabbri, Agnese
    Rossi, Luigi
    Verrazzo, Annarita
    Scafetta, Roberta
    Marinelli, Daniele
    Sposetti, Caterina
    Barberi, Vittoria
    Strigari, Lidia
    Marchetti, Paolo
    Santini, Daniele
    Fabi, Alessandra
    ONCOLOGIST, 2024, 29 (04): : 303 - 310
12345